UNLABELLED: A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resistance and poor outcome using biologically specific PET agents. This approach was investigated using a multiagent imaging protocol for which patients were imaged in a single session to minimize changes in tumor parameters caused by multiple-day and -setting observation differences. METHODS: We present data from a pilot study in 10 soft-tissue sarcoma patients imaged with (11)C-thymidine for cellular proliferation, (18)F-fluoromisonidazole (FMISO) for tissue hypoxia, and (11)C-verapamil for P-glycoprotein activity, in comparison with (15)O-water for blood flow and (11)C-CO(2) for metabolite analysis and (18)F-FDG clinical scans. Several patients underwent repeated imaging after adriamycin-based chemotherapy. RESULTS: Quantitative imaging results showed that tumor uptake parameters vary between patients and with respect to each other in individual patients, suggesting that each patient's tumor biologic profile is unique. Specific tumor characteristics such as variable cellular proliferation, hypoxic volume, and upregulated P-glycoprotein activity were identified. CONCLUSION: This study shows that multiagent PET is feasible and yields unique and potentially complementary biologic information on individual tumors.
UNLABELLED: A major goal of molecular imaging in cancer is to evaluate patienttumors for risk of treatment resistance and poor outcome using biologically specific PET agents. This approach was investigated using a multiagent imaging protocol for which patients were imaged in a single session to minimize changes in tumor parameters caused by multiple-day and -setting observation differences. METHODS: We present data from a pilot study in 10 soft-tissue sarcomapatients imaged with (11)C-thymidine for cellular proliferation, (18)F-fluoromisonidazole (FMISO) for tissue hypoxia, and (11)C-verapamil for P-glycoprotein activity, in comparison with (15)O-water for blood flow and (11)C-CO(2) for metabolite analysis and (18)F-FDG clinical scans. Several patients underwent repeated imaging after adriamycin-based chemotherapy. RESULTS: Quantitative imaging results showed that tumor uptake parameters vary between patients and with respect to each other in individual patients, suggesting that each patient's tumor biologic profile is unique. Specific tumor characteristics such as variable cellular proliferation, hypoxic volume, and upregulated P-glycoprotein activity were identified. CONCLUSION: This study shows that multiagent PET is feasible and yields unique and potentially complementary biologic information on individual tumors.
Authors: Kenneth A Krohn; Finbarr O'Sullivan; John Crowley; Janet F Eary; Hannah M Linden; Jeanne M Link; David A Mankoff; Mark Muzi; Joseph G Rajendran; Alexander M Spence; Kristin R Swanson Journal: Nucl Med Biol Date: 2007-10 Impact factor: 2.408
Authors: N M Alpert; L Eriksson; J Y Chang; M Bergstrom; J E Litton; J A Correia; C Bohm; R H Ackerman; J M Taveras Journal: J Cereb Blood Flow Metab Date: 1984-03 Impact factor: 6.200
Authors: A M Spence; M Muzi; M M Graham; F O'Sullivan; K A Krohn; J M Link; T K Lewellen; B Lewellen; S D Freeman; M S Berger; G A Ojemann Journal: J Nucl Med Date: 1998-03 Impact factor: 10.057
Authors: J F Eary; D A Mankoff; A M Spence; M S Berger; A Olshen; J M Link; F O'Sullivan; K A Krohn Journal: Cancer Res Date: 1999-02-01 Impact factor: 12.701
Authors: David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Erin K Schubert; Jeffrey Tseng; Thomas J Lawton; Hannah M Linden; Robert B Livingston Journal: J Nucl Med Date: 2003-11 Impact factor: 10.057
Authors: Joanne M Wells; David A Mankoff; Mark Muzi; Finbarr O'Sullivan; Janet F Eary; Alexander M Spence; Kenneth A Krohn Journal: Mol Imaging Date: 2002-07 Impact factor: 4.488
Authors: Joanne M Wells; David A Mankoff; Janet F Eary; Alexander M Spence; Mark Muzi; Finbarr O'Sullivan; Cheryl B Vernon; Jeanne M Link; Kenneth A Krohn Journal: Mol Imaging Date: 2002-07 Impact factor: 4.488
Authors: P H Elsinga; E J Franssen; N H Hendrikse; L Fluks; A M Weemaes; W T van der Graaf; E G de Vries; G M Visser; W Vaalburg Journal: J Nucl Med Date: 1996-09 Impact factor: 10.057
Authors: Johannes Salamon; Thorsten Derlin; Peter Bannas; Jasmin D Busch; Jochen Herrmann; Maximilian Bockhorn; Christian Hagel; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner Journal: Eur J Nucl Med Mol Imaging Date: 2012-12-12 Impact factor: 9.236
Authors: Johannes Salamon; Simon Veldhoen; Ivayla Apostolova; Peter Bannas; Jin Yamamura; Jochen Herrmann; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner; Thorsten Derlin Journal: Eur Radiol Date: 2013-10-05 Impact factor: 5.315
Authors: Inessa Semenenko; Emma Portnoy; Mohammed Aboukaoud; Serge Guzy; Miriam Shmuel; Gal Itzhak; Sara Eyal Journal: Front Pharmacol Date: 2016-11-15 Impact factor: 5.810
Authors: Ramon F Barajas; Kenneth A Krohn; Jeanne M Link; Randall A Hawkins; Jennifer L Clarke; Miguel H Pampaloni; Soonmee Cha Journal: Biomedicines Date: 2016-10-31